HAE

BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026. The call can be accessed via teleconference at: Q1 2027 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start. A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/r8e9tnfy A replay of the conference call and webcast will be available for one year beginning on August 6, 2026 at 11:00 am ET using the conference call webcast link provided in this press release. ABOUT HAEMONETICS Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com. View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-first-quarter-fiscal-year-2027-results-august-6-2026-302821033.html

Earlier this week, Haemonetics reported quarterly results that surpassed analyst expectations for both revenue and earnings, supported by solid demand in its plasma and hospital-focused product lines. The earnings beat, combined with BofA Securities upgrading the stock on improving vascular closure and plasma performance, has sharpened investor focus on the company’s product mix and execution quality. We’ll now examine how the earnings beat and raised guidance may influence Haemonetics’ existing investment narrative and long-term thesis. Uncover the next big thing with 25 elite penny stocks that balance risk and reward. To own Haemonetics, you need to believe that its core plasma, hospital, and vascular closure franchises can compound value through steady demand and disciplined execution. The latest earnings beat and raised EPS guidance support that view and keep vascular closure performance as the key near term catalyst, while execution risk in a concentrated U.S. portfolio remains the biggest concern. So far, this quarter’s news appears to reinforce the existing thesis rather than change it in a material way. Among recent developments, BofA Securities’ upgrade and higher price target directly tie into this quarter’s strength in vascular closure and plasma. That call brought fresh attention to whether Haemonetics can turn recent product wins, new FDA clearances, and software upgrades into sustained growth in its three core platforms. For investors watching near term share performance, the alignment between the earnings surprise, raised guidance, and the BofA upgrade is particularly relevant to the current catalyst path. Yet beneath the positive headlines, investors should also be aware of how concentrated U.S. exposure leaves Haemonetics more vulnerable if... Read the full narrative on Haemonetics (it's free!) Haemonetics’ narrative projects $1.5 billion revenue and $247.6 million earnings by 2029. Uncover how Haemonetics' forecasts yield a $86.90 fair value, a 33% upside to its current price. Some of the lowest ranked analysts were already cautious, assuming revenue would only reach about US$1.5 billion and earnings US$252.5 million by 2029, and they worry that dependence on flat U.S. plasma volumes could limit the payoff from this quarter’s beat and vascular closure momentum. Explore 2 other fair value estimates on Haemonetics - why the stock might be wor...

Haemonetics Corporation HAE delivered fourth-quarter fiscal 2026 adjusted earnings of $1.29 per share, up 4.0% year over year. The figure beat the Zacks Consensus Estimate by 1.0%. On a GAAP basis, loss per share was 44 cents compared to earnings of of $1.17 per share in the prior-year quarter. HAE posted adjusted earnings per share of $4.96 for fiscal 2026, up from $4.57 in fiscal 2025. Revenues rose 4.8% from the year-ago period’s level to $346.35 million, topping the Zacks Consensus Estimate by 2.4%. For fiscal 2026, the company generated total revenues of $1.33 billion, down 2.0% from the prior-year figure. Strength across the company’s core platforms stood out, with organic revenue growth of 4.5% and organic growth excluding CSL impacts of 8.6%, helping offset continued softness in interventional technologies. Following the earnings announcement, HAE’s shares rose 1.4% last Friday. At Plasma, revenues totaled $130.3 million, up 2.8% year over year (up 1.8% on an organic basis). Organic growth, excluding CSL impacts, was 12.7%, reflecting continued momentum in the franchise. Revenues at Blood Center increased 0.7% to $56.4 million (up 5.5% on an organic basis). The segment’s organic performance reflected the benefit of portfolio-adjusted growth. Hospital revenues rose 8.0% to $159.6 million (up 6.5% organically). In the fourth quarter of fiscal 2026, gross profit increased 2.7% to $198.2 million. Gross margin contracted 120 basis points (bps) year over year to 57.2% as cost of goods sold rose 7.7% to $148.1 million. Selling, general and administrative expenses increased 5.6% to $121.8 million, while research and development expenses declined 9.2% to $14.4 million. Total operating expenses jumped 81.8% to $221.2 million, driving an operating loss of $23.0 million compared to operating income of $71.3 million in the prior-year quarter. Haemonetics ended fiscal 2026 with $245.4 million in cash and cash equivalents compared to $306.8 million at the end of fiscal 2025. Cumulative net cash flow at the end of fiscal fourth-quarter 2026 was $293.2 million compared with $181.7 million a year ago. Haemonetics Corporation price-consensus-eps-surprise-chart | Haemonetics Corporation Quote Management expects reported revenue growth of 4-7%, including an estimated 53rd-week impact of roughly 2% and a currency impact of 0-1%. Organic revenue growth is projected at 3-6%...

Interested in Haemonetics Corporation? Here are five stocks we like better. Haemonetics reported fiscal Q4 revenue of $346 million, up 5% reported and 9% organically excluding CSL, with adjusted EPS of $1.29. For the full year, revenue reached $1.3 billion and adjusted EPS was $4.96, helped by stronger margins and free cash flow. Plasma and Blood Management Technologies were the main growth drivers, while Interventional Technologies remained weak. Plasma grew 13% organically in the quarter, and Blood Management Technologies posted a record quarter, but Interventional Technologies revenue fell 10% due to softness in vascular closure and related procedures. Fiscal 2027 guidance calls for reported revenue growth of 4% to 7% and adjusted operating margin expansion of 50 to 100 basis points. The company also said it expects continued momentum from Plasma, modest Hospital growth, and no revenue contribution yet from PerQseal Elite while it awaits FDA review. Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies. President and CEO Christopher Simon said the company delivered adjusted earnings of $1.29 per share in the quarter, up 4% from a year earlier. For fiscal 2026, Haemonetics reported revenue of $1.3 billion and adjusted earnings of $4.96 per share, with Simon citing higher adjusted margins and stronger free cash flow despite $153 million of non-recurring revenue impacts from portfolio transitions. → Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance “Our performance reflects the strength of our core platforms, with Plasma and TEG driving momentum, margin expansion, and reinforcing our leadership in attractive end markets,” Simon said. Plasma revenue was $130 million in the fourth quarter, up 3% reported and 13% organically excluding CSL, as Haemonetics annualized the final effects of the discontinued CSL U.S. disposable supply agreement. Full-year Plasma revenue was $524 million, down 2% reported but up 20% organically excluding CSL, above the company’s revised guidance range of 17% to 19%. → MarketBeat Week in Review – 05/04 - 05/08 Simon said Plasma benefited from market fundamentals including resilient immunoglobulin demand and expansion in g...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Successfully navigated $153 million in nonrecurring revenue headwinds from portfolio transitions, clearing the path for a 'clean' growth profile in fiscal 2027. Plasma growth was driven by a 'trifecta' of price gains from Persona, meaningful market share expansion, and a return to double-digit collection volume growth late in the year. Interventional Technologies (IVT) reached a strategic inflection point in Q4, with 80% of fiscal 2026 declines attributed to lapped OEM inventory rebalancing and PFA-related headwinds. Blood Management Technologies achieved record performance fueled by TEG 6s capital placements and the successful European launch of the HN cartridge. Operational excellence initiatives and portfolio rationalization, including the whole blood divestiture, drove a structural 280 basis point expansion in adjusted gross margin for the full year. Strategic investments in the commercial organization and R&D were accelerated in Q4 to prepare for a robust cycle of product launches in the coming fiscal year. Revenue guidance assumes a prudent 0% to 2% plasma collection volume growth, providing potential upside if market trends remain strong or Persona PLUS adoption accelerates. Operating margin expansion of 50 to 100 basis points is expected to be driven by favorable mix shifts toward high-margin hospital products and volume-driven leverage. The Vivasure acquisition was approximately $0.05 dilutive in Q4, which would extrapolate to roughly $0.20 for a full year, and the company's current guidance excludes any potential revenue contribution from the platform pending further results. Management expects adjusted EPS to grow in line with reported revenue, as operating leverage gains are partially offset by higher anticipated interest and tax rates. Free cash flow conversion is targeted at approximately 80%, reflecting a disciplined approach to working capital and planned inventory increases to support new product launches. Tariff impacts were concentrated in Q4 as plasma inventories depleted; guidance assumes a 15% tariff level versus the current 10% rate. The Blood Center franchise is expected to decline in the mid-single digits due to ongoing intentional portfolio rationalization efforts. Self-insured medi...

Image source: The Motley Fool. Thursday, May 7, 2026 at 8 a.m. ET Chief Executive Officer — Christopher Simon Chief Financial Officer — James D'Arecca Vice President, Investor Relations — Olga Guyette Need a quote from a Motley Fool analyst? Email [email protected] Olga Guyette: Good morning, and thank you for joining us for Haemonetics' Fourth Quarter Fiscal Year 2026 Conference Call and Webcast. I'm joined today by Chris Simon, our CEO; and James D'Arecca, our CFO. This morning, we released our fourth quarter and full fiscal 2026 results and issued fiscal year 2027 guidance. The materials, including our earnings release and supplemental earnings presentation, are available on our Investor Relations website and also in this morning's press release. Before we begin, I'd like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of FX, the divestiture of the whole blood product line, and the exit of certain liquid solutions products. Organic growth ex-CSL also excludes the impact of the previously disclosed transition of CSL's U.S. disposable business. Our fiscal year 2027 organic revenue guidance is also adjusted for the impact of the 53rd week. We'll refer to other non-GAAP financial measures to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results and comparisons with the prior year periods are provided in our earnings release. Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's earnings release and in other SEC filings. We do not undertake any obligation to update these forward-looking statements. And now, I'd like to turn it over to Chris. Christopher Simon: Thanks, Olga, and good morning, everyone. We delivered fourth quarter revenue of $346 million, up 5% reported and 9% organic ex-CSL, with adjusted EPS of $1.29, up 4% year-over-year. For the full fiscal year, revenue was $1.3 billion, and adjusted EPS was $4.96 per share with improved adjusted earnings, higher adjusted margins, and stronger free cash flow than in the prior year despite $153 million of nonrecurring rev...

For the quarter ended March 2026, Haemonetics (HAE) reported revenue of $346.35 million, up 4.8% over the same period last year. EPS came in at $1.29, compared to $1.24 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $338.14 million, representing a surprise of +2.43%. The company delivered an EPS surprise of +1.04%, with the consensus EPS estimate being $1.28. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Haemonetics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net revenues- Plasma: $130.3 million versus the three-analyst average estimate of $125.9 million. The reported number represents a year-over-year change of +2.8%. Net revenues- Hospital: $159.6 million compared to the $158.21 million average estimate based on three analysts. The reported number represents a change of +7.9% year over year. Net revenues- Blood Center: $56.4 million compared to the $53.13 million average estimate based on three analysts. The reported number represents a change of +0.7% year over year. View all Key Company Metrics for Haemonetics here>>> Shares of Haemonetics have returned -11.5% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Haemonetics Corporation (HAE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Haemonetics (HAE) reported fiscal Q4 adjusted earnings Thursday of $1.29 per diluted share, up from

BOSTON (AP) — BOSTON (AP) — Haemonetics Corp. (HAE) on Thursday reported a loss of $20.1 million in its fiscal fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 44 cents. Earnings, adjusted for asset impairment costs and amortization costs, came to $1.29 per share. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.28 per share. The provider blood management systems for health care providers and blood collectors posted revenue of $346.4 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $338.1 million. For the year, the company reported profit of $97.3 million, or $2.05 per share. Revenue was reported as $1.33 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HAE at https://www.zacks.com/ap/HAE

Envista (NVST) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +16.13%. A quarter ago, it was expected that this maker of dental products would post earnings of $0.32 per share when it actually produced earnings of $0.38, delivering a surprise of +18.75%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Envista, which belongs to the Zacks Medical - Products industry, posted revenues of $705.5 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.75%. This compares to year-ago revenues of $616.9 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Envista shares have added about 20.6% since the beginning of the year versus the S&P 500's gain of 6%. While Envista has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Envista was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks her...

Financial release and supplemental presentation accessible online BOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026. Conference Call and Webcast Information: Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended. Live webcast: Access here or through the Investor Relations section of the Haemonetics website. A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on May 7, 2026 and will remain accessible for one year via the webcast link above. Earnings Materials: Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast: Fourth Quarter Fiscal 2026 Earnings Release Fourth Quarter Fiscal 2026 Supplemental Earnings Presentation ABOUT HAEMONETICS Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com. Investor Contacts: Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 [email protected] David Trenk, Manager-Investor Relations (203) 733-4987 [email protected] Media Contact: Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-fourth-quarter-fiscal-2026-financial-results-available-on-investor-relations-website-302764893.html

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.04%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $1.27 per share when it actually produced earnings of $1.31, delivering a surprise of +3.15%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Haemonetics, which belongs to the Zacks Medical - Products industry, posted revenues of $346.35 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 2.43%. This compares to year-ago revenues of $330.6 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Haemonetics shares have lost about 34.3% since the beginning of the year versus the S&P 500's gain of 7.6%. While Haemonetics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Haemonetics was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. Y...